Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and …
Promising results have been reported for patients with high-risk hematologic malignancies
undergoing T-cellreplete myeloablative hematopoietic stem cell transplantation (HSCT) from
HLA-haploidentical donors with post-transplantation cyclophosphamide (PT/Cy). Here, we
report the largest patient experience (n= 97) for leukemias in complete remission (CR) and
chemosensitive lymphomas with at least a partial remission (PR) enrolled on, or treated
according to, our now completed single-institution phase II clinical trial. Conditioning …
undergoing T-cellreplete myeloablative hematopoietic stem cell transplantation (HSCT) from
HLA-haploidentical donors with post-transplantation cyclophosphamide (PT/Cy). Here, we
report the largest patient experience (n= 97) for leukemias in complete remission (CR) and
chemosensitive lymphomas with at least a partial remission (PR) enrolled on, or treated
according to, our now completed single-institution phase II clinical trial. Conditioning …